Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Heudel

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Cancer Care|September 28, 2022
The Ambulatory Medical Assistance (AMA) programme during active-phase treatment in patients with haematological malignancies: A cost-effectiveness analysisAnne-Sophie Michallet, Stephanie Malartre, Elodie Vignaud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2022
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patientsPierre Heudel, Bertrand Favier, Marie-Laure Solodky, et al.
Cancer Communications (London, England)|June 19, 2026
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life ConsequencesDamien Bruyat, Nicolas Girard, Pierre Heudel, et al.
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
Oncology Letters|March 22, 2016
Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort studyFrédéric Selle, George Emile, Patricia Pautier, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
International Journal of Environmental Research and Public Health|February 24, 2024
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer ResearchJulien Guérin, Amine Nahid, Louis Tassy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programmeRomain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Anticancer Research|July 5, 2020
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC StudyPierre Heudel, Suzette Delaloge, Damien Parent, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Cancer Care|September 28, 2022
The Ambulatory Medical Assistance (AMA) programme during active-phase treatment in patients with haematological malignancies: A cost-effectiveness analysisAnne-Sophie Michallet, Stephanie Malartre, Elodie Vignaud, et al.
European Journal of Cancer (Oxford, England : 1990)|March 4, 2022
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patientsPierre Heudel, Bertrand Favier, Marie-Laure Solodky, et al.
Cancer Communications (London, England)|June 19, 2026
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life ConsequencesDamien Bruyat, Nicolas Girard, Pierre Heudel, et al.
JAMA Oncology|May 13, 2022
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical TrialPierre Heudel, Jean-Sébastien Frenel, Cécile Dalban, et al.
Oncology Letters|March 22, 2016
Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort studyFrédéric Selle, George Emile, Patricia Pautier, et al.
Oncoimmunology|July 4, 2012
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patientsManuarii Manuel, Olivier Tredan, Thomas Bachelot, et al.
International Journal of Environmental Research and Public Health|February 24, 2024
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer ResearchJulien Guérin, Amine Nahid, Louis Tassy, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programmeRomain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Anticancer Research|July 5, 2020
Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC StudyPierre Heudel, Suzette Delaloge, Damien Parent, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
Pageof 3